These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9034931)

  • 41. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients.
    Turlin B; Mendler MH; Moirand R; Guyader D; Guillygomarc'h A; Deugnier Y
    Am J Clin Pathol; 2001 Aug; 116(2):263-70. PubMed ID: 11488074
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Iron and liver fibrosis: Mechanistic and clinical aspects.
    Mehta KJ; Farnaud SJ; Sharp PA
    World J Gastroenterol; 2019 Feb; 25(5):521-538. PubMed ID: 30774269
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Wnt signaling in liver fibrosis: progress, challenges and potential directions.
    Miao CG; Yang YY; He X; Huang C; Huang Y; Zhang L; Lv XW; Jin Y; Li J
    Biochimie; 2013 Dec; 95(12):2326-35. PubMed ID: 24036368
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatocyte apoptosis in hepatic iron overload diseases.
    Zhao M; Laissue JA; Zimmermann A
    Histol Histopathol; 1997 Apr; 12(2):367-74. PubMed ID: 9151125
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Proteomic analysis of hepatic iron overload in mice suggests dysregulation of urea cycle, impairment of fatty acid oxidation, and changes in the methylation cycle.
    Petrak J; Myslivcova D; Man P; Cmejla R; Cmejlova J; Vyoral D; Elleder M; Vulpe CD
    Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1490-8. PubMed ID: 17307722
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HFE gene in primary and secondary hepatic iron overload.
    Sebastiani G; Walker AP
    World J Gastroenterol; 2007 Sep; 13(35):4673-89. PubMed ID: 17729389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Iron overload and liver diseases (except for hemochromatosis and dysmetabolic hepatosiderosis].
    Dhumeaux D; Hezode C
    Bull Acad Natl Med; 2000; 184(2):349-54. PubMed ID: 10989543
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epigenetic modifications in hepatic stellate cells contribute to liver fibrosis.
    Zhao Q; Qin CY; Zhao ZH; Fan YC; Wang K
    Tohoku J Exp Med; 2013 Jan; 229(1):35-43. PubMed ID: 23238615
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition.
    Di Marco V; Bronte F; Cabibi D; Calvaruso V; Alaimo G; Borsellino Z; Gagliardotto F; Almasio PL; Capra M; Craxì A
    Br J Haematol; 2010 Feb; 148(3):476-9. PubMed ID: 19930183
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Resveratrol mediates therapeutic hepatic effects in acquired and genetic murine models of iron-overload.
    Das SK; DesAulniers J; Dyck JR; Kassiri Z; Oudit GY
    Liver Int; 2016 Feb; 36(2):246-57. PubMed ID: 26077449
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Increased hepatic iron and cirrhosis: no evidence for an adverse effect on patient outcome following liver transplantation.
    Stuart KA; Fletcher LM; Clouston AD; Lynch SV; Purdie DM; Kerlin P; Crawford DH
    Hepatology; 2000 Dec; 32(6):1200-7. PubMed ID: 11093725
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C.
    Di Marco V; Capra M; Gagliardotto F; Borsellino Z; Cabibi D; Barbaria F; Ferraro D; Cuccia L; Ruffo GB; Bronte F; Di Stefano R; Almasio PL; Craxì A
    Haematologica; 2008 Aug; 93(8):1243-6. PubMed ID: 18556410
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of Liver Fibrotic Insults In Vitro.
    Perea L; Coll M; Sancho-Bru P
    Methods Mol Biol; 2015; 1250():391-401. PubMed ID: 26272160
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatic iron overload or cirrhosis may occur in acquired copper deficiency and is likely mediated by hypoceruloplasminemia.
    Thackeray EW; Sanderson SO; Fox JC; Kumar N
    J Clin Gastroenterol; 2011 Feb; 45(2):153-8. PubMed ID: 20502350
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transfusional siderosis and liver cirrhosis.
    Sinniah R
    J Clin Pathol; 1969 Sep; 22(5):567-72. PubMed ID: 5364442
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Autosomal dominant iron overload due to a novel mutation of ferroportin1 associated with parenchymal iron loading and cirrhosis.
    Wallace DF; Clark RM; Harley HA; Subramaniam VN
    J Hepatol; 2004 Apr; 40(4):710-3. PubMed ID: 15030991
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Iron and the liver.
    Corradini E; Ferrara F; Pietrangelo A
    Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():245-8. PubMed ID: 16462704
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
    N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver.
    Loria P; Lonardo A; Carulli N
    Hepatology; 2004 Jun; 39(6):1748; author reply 1749. PubMed ID: 15185321
    [No Abstract]   [Full Text] [Related]  

  • 60. Kupffer cell iron overload induces intercellular adhesion molecule-1 expression on hepatocytes in genetic hemochromatosis.
    Stål P; Broomé U; Scheynius A; Befrits R; Hultcrantz R
    Hepatology; 1995 May; 21(5):1308-16. PubMed ID: 7737636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.